Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3943582 | 1.00 | DRD2 (0.49) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL352832 | 1.00 | DRD2 (0.49) | DRD2BTKEPHX1KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL3513679 | 0.98 | DRD2 (0.48) | DRD2BTKEPHX1KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL30722908 | 0.98 | DRD2 (0.48) | DRD2BTKEPHX1KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL3513680 | 0.98 | DRD2 (0.48) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL3900940 | 0.90 | BTK (0.54) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL5549963 | 0.90 | BTK (0.54) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL3899249 | 0.90 | BTK (0.54) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL5524221 | 0.90 | BTK (0.54) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL23185506 | 0.89 | DRD2 (0.50) | DRD2BTKEPHX1KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454525-B2 | IL4I1 inhibitors and methods of use | MERCK SHARP & DOHME LLC (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4634169-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | Pfizer Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| WO-2025106771-A1 | SMALL MOLECULES TO INCREASE NAD LEVELS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20250163043-A1 | CDK9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-05-22 | — | — | US | disclosed |
| US-20250127800-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE AND MEDICINAL USE THEREOF | SIGNET THERAPEUTICS INC. (CN) | 2025-04-24 | — | — | US | disclosed |
| WO-2025045758-A1 | ANTIBODY-DRUG CONJUGATES BASED ON MOLECULAR GLUE DEGRADERS AND USES THEREOF | MABLINK BIOSCIENCE (FR) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025045761-A1 | MOLECULAR GLUE DEGRADERS AND USES THEREOF | MABLINK BIOSCIENCE (FR) | 2025-03-06 | — | — | WO | disclosed |
| EP-4512806-A1 | MOLECULAR GLUE DEGRADERS AND USES THEREOF | Mablink Bioscience (FR) | 2025-02-26 | — | — | EP | disclosed |
| EP-4512427-A1 | ANTIBODY-DRUG CONJUGATES BASED ON MOLECULAR GLUE DEGRADERS AND USES THEREOF | Mablink Bioscience (FR) | 2025-02-26 | — | — | EP | disclosed |
| EP-4472974-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Schrödinger, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2000018764-A1 | BENZIMIDAZOLINYL PIPERIDINES AS CGRP LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 2000-04-06 | — | — | WO | disclosed |
| WO-1999022735-A1 | SOMATOSTATIN AGONISTS | MERCK & CO., INC. (US) | 1999-05-14 | — | — | WO | disclosed |
| EP-0835109-A4 | PYRIDINONE-THROMBIN INHIBITORS | MERCK & CO INC (US) | 1999-02-03 | — | — | EP | disclosed |
| WO-1998044921-A1 | SOMATOSTATIN AGONISTS | MERCK & CO., INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| US-5744486-A | Pyridinone thrombin inhibitors | MERCK & CO., INC. (US) | 1998-04-28 | — | — | US | disclosed |
| EP-0835109-A1 | PYRIDINONE-THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 1998-04-15 | — | — | EP | disclosed |
| US-5714485-A | Piperidine and hexahydropyridazine thrombin inhibitors | MERCK & CO., INC. (US) | 1998-02-03 | — | — | US | disclosed |
| US-5668289-A | Pyridinone thrombin inhibitors | MERCK & CO., INC. (US) | 1997-09-16 | — | — | US | disclosed |
| WO-1997001338-A1 | PYRIDINONE-THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1997-01-16 | — | — | WO | disclosed |
| US-5510369-A | ANTICOAGULANTS | MERCK & CO., INC. (US) | 1996-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163043-A1 | CDK9 INHIBITOR AND USE THEREOF | CDK9, CDK19, CDKL1 | DRD2 3418/4885BTK 759/4885EPHX1 1983/4885 |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | IL4I1, IL4, IL2 | DRD2 4869/4885BTK 2059/4885EPHX1 1319/4885 |
| US-20250127800-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE AND MEDICINAL USE THEREOF | PTK2, PDGFRB, PTK2B | DRD2 3537/4885BTK 186/4885EPHX1 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.